Drug retailers feel the heat as Amazon launches online pharmacy
Shares of drug retailers such as CVS Health Corp (NYSE: CVS) and Walgreens Boots Alliance Inc. (NASDAQ: WBA) fell in the mid-day trading Tuesday following the news.
Staff or Guest writer for The Dog of Wall Street.
2020-11-17 12:53

Amazon.com Inc. has launched an online pharmacy for selling prescription medicines across the U.S. Shares of drug retailers such as CVS Health Corp (NYSE: CVS) and Walgreens Boots Alliance Inc. (NASDAQ: WBA) fell in the mid-day trading Tuesday following the news. 

The new store, named Amazon Pharmacy, will allow customers to compare prices of the medicines on the app. They can choose between their copayment and a non-insurance option while checking out. Amazon will offer heavy discount to its prime members on the store. 

The Seattle, Washington-based company has disrupted many industries along its tremendous growth journey. Amazon, which initially started its operations as an online bookseller, has been giving tough competition to companies in the retail and computing industries, and now the leading players in the pharmaceutical market will also face the heat after the latest announcement. The company has also faced criticism from labor groups and regulators in the past over its size and power. 

The e-commerce giant’s new venture will now directly compete with Walgreens Boots, CVS Health, Walmart, Rite Aid, Kroger, and others. Online purchase of medicines has been relatively low as compared to physical store purchases. However, the pandemic may drive the online sales of drugs. 

In case of Amazon, its prime members maybe more inclined to order drugs online through its newly opened store, as the company is offering up to 80 percent discount on generic and up to 40 percent discount on brand drugs when prime members decide to pay without insurance. 

Amazon (NASDAQ: AMZN) shares slightly moved up in the mid-day trading Tuesday. If we look at the performance of the stock in the recent months, the stock has jumped more than 70 percent on year-to-date basis, about +31 percent over the past 6 months, and stayed nearly flat during the past 3 months.

Disclaimer: I have no positions in any of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article. All information should be independently verified and should not be relied upon for purposes of transacting securities or other investments. See terms for more info.

Published On
2020-11-17 12:53

About the Author
Staff or Guest writer for The Dog of Wall Street.

Analyst Ratings
Target Price $4264.77
# of Analysts 49
Last updated 2021-07-29

2 FinTwit Stocks I'm Bearish On
If you have ready my past articles, you know I generally like to write about companies I am bullish on.
By Mike Sakuraba | 2 days ago

3 Stocks That Need to Split
In commemoration of NVIDIA’s (NASDAQ:NVDA) recent 4 for 1 stock split, it’s time to scan the markets for some other candidates.
By Mike Sakuraba | 4 days ago

2 Stocks for a Bearish Summer
We’ve heard the warnings for months now: a substantial bearish correction will hit the markets soon.
By Mike Sakuraba | 1 week ago

Investing in Space Travel
Forecasting pre-revenue companies and sectors is an interesting financial exercise
By Mike Sakuraba | 2 weeks ago

Netflix is Still the Streaming King
Early on in the COVID-19 pandemic, Netflix (NASDAQ:NFLX) was heralded as one of the big winners of the new stay at home economy.
By Mike Sakuraba | 1 month ago

What's Next for GameStop?
On Wednesday after the closing bell, GameStop (NYSE:GME) held its annual shareholders meeting which it also used to report its quarterly results.
By Mike Sakuraba | 1 month ago